

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF CR PHARMACEUTICAL COMMERCIAL FOR THE SIX MONTHS ENDED 30 JUNE 2026 IN RELATION TO ISSUANCE OF MEDIUM TERM NOTES AND CORPORATE BONDS IN THE PRC

Reference is made to: (i) the announcement dated 1 December 2025 in relation to, among others, the proposed issuance of medium term notes in the PRC by China Resources Pharmaceutical Commercial Group Company Limited (華潤醫藥商業集團有限公司) (“**CR Pharmaceutical Commercial**”), a non-wholly-owned subsidiary of the Company; (ii) the announcement dated 15 December 2025 in relation to, among others, the completion of the issuance of the first tranche of medium term notes for the year of 2025 in the PRC by CR Pharmaceutical Commercial; (iii) the announcement dated 27 March 2026 in relation to, among others, the completion of the issuance of the first tranche of corporate bonds in 2026 in the PRC by CR Pharmaceutical Commercial; (iv) the announcement dated 28 April 2026 in relation to, among others, the completion of the issuance of the second tranche of corporate bonds in 2026 in the PRC by CR Pharmaceutical Commercial; and (v) the announcement dated 26 June 2026 in relation to, among others, the completion of the issuance of the third tranche of corporate bonds in 2026 in the PRC by CR Pharmaceutical Commercial (the “**Announcements**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless stated otherwise herein.

In accordance with the relevant rules and regulations in the PRC and in connection with its issuance of medium term notes and corporate bonds in the PRC, CR Pharmaceutical Commercial has published its unaudited financial statements for the six months ended 30 June 2026 on the websites of China Money and Shanghai Clearing House in connection with the medium term notes, and on the websites of the Shanghai Stock Exchange and the Shenzhen Stock Exchange in connection with the corporate bonds.

The unaudited financial statements of CR Pharmaceutical Commercial for the six months ended 30 June 2026 (the “**Unaudited Financial Statements of CR Pharmaceutical Commercial**”) are enclosed to this announcement for the Company’s shareholders’ information only. The Unaudited Financial Statements of CR Pharmaceutical Commercial were prepared in Chinese and have been translated for publication in English and Chinese. In the event of any inconsistency between the two versions, the Chinese version shall prevail. In addition, the Unaudited Financial Statements of CR Pharmaceutical Commercial have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company’s auditors, and may require adjustments during the course of auditing. Such financial information is limited to CR Pharmaceutical Commercial only and does not represent or provide a complete view of the operational or financial status of the Group.

Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 31 August 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mdm. Zhang Jing and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.

**CHINA RESOURCES PHARMACEUTICAL COMMERCIAL GROUP
COMPANY LIMITED
CONSOLIDATED BALANCE SHEET
JUNE 2026**

Unit: RMB

Item	30 June 2026	31 December 2025	Item	30 June 2026	31 December 2025
Current assets:			Current liabilities:		
Monetary fund	10,566,408,988.70	10,257,067,215.35	Short-term borrowings	39,772,803,913.63	33,455,137,520.39
Notes receivable	238,340,569.98	241,598,060.17	Notes payable	18,725,456,190.62	20,489,498,505.52
Accounts receivable	87,987,960,862.41	81,953,462,510.56	Accounts payable	43,346,728,897.50	39,973,927,485.76
Financing receivables	10,792,352,103.53	9,314,180,265.98	Contract liabilities	1,656,152,452.15	1,567,788,033.34
Prepayment	3,363,496,949.93	3,550,359,009.85	Staff remuneration payable	971,115,808.07	1,095,089,453.36
Other receivables	6,662,109,837.76	5,660,783,137.51	Taxation payable	638,462,708.30	706,961,740.62
Inventory	35,447,979,499.71	33,397,894,883.62	Other payables	8,040,776,333.05	7,558,385,842.13
Contract assets	21,154,593.05	36,368,075.40	Non-current liabilities due within one year	6,640,446,210.76	5,347,902,389.66
Non-current assets due within one year	–	–	Other current liabilities	144,549,191.57	116,541,074.19
Other current assets	1,479,815,587.54	1,555,535,755.91			
Total current assets	156,559,618,992.61	145,967,248,914.35	Total current liabilities	119,936,491,705.65	110,311,232,044.97
Non-current assets:			Non-current liabilities:		
Long-term receivables	690,553,825.79	804,033,995.94	Long-term borrowings	3,243,722,165.89	6,235,411,075.59
Other equity instruments investments	2,066,000.00	2,066,000.00	Bonds payable	11,998,746,933.94	7,996,868,303.42
Long-term equity investments	2,055,834,163.11	1,981,171,228.00	Long-term payables	168,438,874.67	163,142,206.67
Investment properties	97,454,392.46	99,246,587.13	Long-term employee remuneration payable	122,451,799.33	120,549,334.37
Other non-current financial assets	23,960,022.62	23,960,022.62	Deferred revenue	19,403,704.03	20,920,263.10
Fixed assets	3,578,163,416.61	3,737,047,170.91	Estimated liabilities	–	–
Right-of-use assets	733,100,485.68	807,820,687.26	Deferred income tax liabilities	223,440,355.92	247,739,539.83
Construction in progress	239,037,346.79	96,931,766.61	Lease liabilities	516,585,073.12	508,652,160.77
Intangible assets	1,864,442,547.87	1,934,472,919.85	Total non-current liabilities	16,292,788,906.90	15,293,282,883.75
Goodwill	9,732,712,191.40	9,732,712,191.40	Total liabilities	136,229,280,612.55	125,604,514,928.72
Long-term deferred expenses	108,749,631.76	133,660,255.99	Owners' equity (or shareholders' equity):		
Deferred income tax assets	1,002,359,402.28	863,531,449.51	Paid-in capital (equity)	19,646,531,357.61	19,646,531,357.61
Other non-current assets	60,123,788.92	59,096,473.50	Other equity instruments	6,000,000,000.00	6,000,000,000.00
Total non-current assets	20,188,557,215.29	20,275,750,748.72	Capital surplus	2,386,026,866.53	2,366,137,504.91
			Other comprehensive income	(33,998,547.63)	(33,858,479.73)
			Surplus reserves	1,284,626,198.44	1,284,626,198.44
			Special reserves	188,214.12	188,214.12
			Undistributed profits	5,535,956,633.78	5,692,606,987.57
			Total equity attributable to owners of the parent company	34,819,330,722.85	34,956,231,782.92
			Minority interests	5,699,564,872.50	5,682,252,951.43
			Total owners' equity	40,518,895,595.35	40,638,484,734.35
Total assets	176,748,176,207.90	166,242,999,663.07	Total liabilities and owners' equity	176,748,176,207.90	166,242,999,663.07

**CHINA RESOURCES PHARMACEUTICAL COMMERCIAL GROUP
COMPANY LIMITED
CONSOLIDATED STATEMENT OF PROFIT OR LOSS
JANUARY TO JUNE 2026**

Unit: RMB

Item	January–June 2026	January–June 2025
Operating revenue	111,562,037,153.78	108,451,915,412.51
Less: Operating costs	104,522,952,747.32	101,485,589,123.97
Tax and surcharge	234,516,783.78	231,458,363.94
Selling expenses	2,781,217,241.36	2,603,963,271.90
Management expenses	1,175,085,278.37	1,238,189,526.47
Research and development expenses	14,439,245.41	23,914,294.54
Finance costs	694,452,097.98	749,630,665.70
Including: Interest expenses	674,341,753.41	754,659,134.93
Interest income	18,107,555.72	44,229,230.02
Add: Other revenue	27,421,832.74	20,822,627.08
Gain from investment	(40,783,433.68)	(21,296,215.25)
Including: Gains from investment in associates and joint ventures	54,669,632.52	69,069,537.24
Gains from changes in fair values	–	(840,290.71)
Impairment losses of assets	(3,617,382.43)	5,253,859.06
Loss on credit impairment	(507,745,895.09)	(551,054,228.91)
Gains from disposal of assets	1,467,878.89	5,614,354.83
Operating profits	1,616,116,759.99	1,577,670,272.09
Add: Non-operating income	15,019,465.10	13,279,577.55
Less: Non-operating expenses	16,736,457.18	14,173,802.72
Total profits	1,614,399,767.91	1,576,776,046.92
Less: Income tax expenses	451,020,677.18	450,075,989.07
Net profits	1,163,379,090.73	1,126,700,057.85
Including: Net profits of the absorbed party before business combination under common control	–	–
Net profits attributable to the owners of the parent company	929,773,368.67	898,760,628.36
*Gains and losses of minority interests	233,605,722.05	227,939,429.49
Other comprehensive income, net of tax	(140,067.90)	144,014.73
Total comprehensive income	1,163,239,022.83	1,126,844,072.58

**CHINA RESOURCES PHARMACEUTICAL COMMERCIAL GROUP
COMPANY LIMITED
CONSOLIDATED STATEMENT OF CASH FLOWS
JANUARY TO JUNE 2026**

Unit: RMB

Item	January–June 2026	January–June 2025
I. Cash flows from operating activities:		
Cash received from the sales of goods and the rendering of services	113,010,781,457.58	108,540,212,318.96
Refund of taxes and levies	328,435.61	13,311.43
Cash received relating to other operating activities	6,535,186,982.45	6,407,697,982.16
Sub-total of cash inflows from operating activities	119,546,296,875.64	114,947,923,612.55
Cash paid for goods purchased and services received	109,454,148,503.47	106,770,127,263.80
Cash paid to and for employees	2,579,129,608.43	2,482,747,656.84
Payments of all types of taxes	2,062,383,618.46	2,007,120,331.36
Cash payments relating to other operating activities	7,552,440,926.45	7,066,527,899.55
Sub-total of cash outflows from operating activities	121,648,102,656.81	118,326,523,151.55
Net cash flow from operating activities	(2,101,805,781.17)	(3,378,599,539.00)
II. Cash Flow From Investing Activities:		
Cash received from investment recovery	90,405,036.31	–
Cash received from returns on investments	585,000.00	24,895,738.93
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	2,754,840.26	4,855,021.21
Net cash received from disposals of subsidiaries and other operating units	–	11,911,840.85
Cash received relating to other investing activities	52,947.94	70,321.11
Sub-total of cash inflows from investing activities	93,797,824.51	41,732,922.10
Cash paid to acquire fixed assets, intangible assets and other long-term assets	220,863,681.70	352,831,289.96
Cash paid for investments	95,000,000.00	–
Net cash paid for acquisition of subsidiaries and other operational units	900,000.00	11,887,769.50
Cash payments relating to other investing activities	781,389.51	–
Sub-total of cash outflows from investing activities	317,545,071.21	364,719,059.46
Net cash flow from investing activities	(223,747,246.70)	(322,986,137.36)

Item	January–June 2026	January–June 2025
III. Cash flow from financing activities:		
Cash received from capital contribution	1,000,000.00	30,500,000.00
Cash received from borrowings	28,844,943,433.52	32,543,818,700.66
Cash received from issuance of bonds	5,200,000,000.00	5,000,000,000.00
Cash payments relating to other financing activities	2,366,362,180.45	2,768,959,330.39
Sub-total of cash inflows from financing activities	36,412,305,613.97	40,343,278,031.05
Cash payments for debts settlement	29,536,945,311.99	31,689,101,756.99
Cash payments for distribution of dividends, profits, or interest expenses	1,902,725,079.14	1,976,598,146.31
Cash payments relating to other financing activities	2,306,968,739.24	2,763,222,188.06
Sub-total of cash outflows from financing activities	33,746,639,130.37	36,428,922,091.36
Net cash flow from financing activities	2,665,666,483.60	3,914,355,939.69
IV. Effect of foreign exchange rate changes on cash and cash equivalents	–	–
V. Net increase in cash and cash equivalents	340,113,455.73	212,770,263.33
Add: Opening balance of cash and cash equivalent	3,951,319,741.63	2,940,907,528.27
VI. Closing balance of cash and cash equivalents	4,291,433,197.36	3,153,677,791.60

**CHINA RESOURCES PHARMACEUTICAL COMMERCIAL GROUP
COMPANY LIMITED
BALANCE SHEET
JUNE 2026**

Unit: RMB

Item	30 June 2026	31 December 2025	Item	30 June 2026	31 December 2025
Current assets:			Current liabilities:		
Monetary fund	3,905,676,544.46	3,782,306,964.46	Short-term borrowings	2,005,790,975.97	484,541,139.63
Accounts receivable	6,584,282,611.96	5,296,570,695.20	Notes payable	1,675,621,388.37	1,581,273,979.00
Financing receivables	244,999,406.17	145,528,497.76	Accounts payable	3,221,272,621.19	2,697,870,457.89
Prepayment	177,872,047.49	221,125,847.99	Contract liabilities	50,830,673.98	14,864,501.34
Other receivables	13,191,010,753.40	11,337,641,504.90	Staff remuneration payable	283,512,328.87	277,989,878.62
Inventory	1,757,517,743.09	1,719,653,237.84	Taxation payable	19,650,169.36	17,016,034.61
Contract assets	5,639,196.50	7,334,667.58	Other payables	11,969,881,828.30	13,754,306,926.13
Non-current assets due within one year	1,200,574,999.99	–	Non-current liabilities due within one year	5,098,471,097.38	3,696,695,892.62
Other current assets	260,707,475.38	236,133,555.18	Other current liabilities	–	1,409,734.07
Total current assets	27,328,280,778.44	22,746,294,970.91	Total current liabilities	24,325,031,083.42	22,525,968,543.91
Non-current assets:			Non-current liabilities:		
Long-term receivables	10,685,158,342.20	11,886,290,354.28	Long-term borrowings	970,000,000.00	3,335,000,000.00
Long-term equity investments	30,019,638,297.24	29,839,529,534.51	Bonds payable	11,998,746,933.94	7,996,868,303.42
Investment properties	4,200,602.90	4,420,658.48	Long-term payables	91,250,872.72	85,954,204.72
Other non-current financial assets	7,416,070.93	7,416,070.93	Long-term employee remuneration payable	85,490,953.20	84,910,684.26
Fixed assets	133,505,524.46	142,478,781.11	Deferred income tax liabilities	10,476,457.11	138,293.50
Right-of-use assets	37,309,604.17	41,905,828.39	Lease liabilities	17,935,967.03	22,605,577.45
Construction in progress	3,693,741.57	9,322,308.51	Total non-current liabilities	13,173,901,184.00	11,525,477,063.35
Intangible assets	54,860,859.00	55,664,535.26	Total liabilities	37,498,932,267.42	34,051,445,607.26
Goodwill	–	–	Owners' equity (or shareholders' equity):		
Long-term deferred expenses	2,916,184.27	3,636,245.93	Paid-in capital (equity)	19,646,531,357.61	19,646,531,357.61
Deferred income tax assets	10,492,909.99	154,746.38	Other equity instruments	6,000,000,000.00	6,000,000,000.00
Other non-current assets	1,518,081.52	1,880,370.82	Capital surplus	3,748,600,793.12	3,728,711,431.50
Total non-current assets	40,960,710,218.25	41,992,699,434.60	Other comprehensive income	(18,555,260.90)	(18,415,193.00)
			Surplus reserves	1,280,741,073.49	1,280,741,073.49
			Undistributed profits	132,740,765.95	49,980,128.65
			Total equity attributable to owners of the parent company	30,790,058,729.27	30,687,548,798.25
			Total owners' equity	30,790,058,729.27	30,687,548,798.25
Total assets	68,288,990,996.69	64,738,994,405.51	Total liabilities and owners' equity	68,288,990,996.69	64,738,994,405.51

**CHINA RESOURCES PHARMACEUTICAL COMMERCIAL GROUP
COMPANY LIMITED
STATEMENT OF PROFIT OR LOSS
JANUARY TO JUNE 2026**

Unit: RMB

Item	January–June 2026	January–June 2025
Operating revenue	9,451,523,746.88	8,916,378,583.41
Less: Operating costs	8,974,579,364.89	8,464,982,865.98
Tax and surcharge	14,438,827.52	15,423,736.40
Selling expenses	211,677,255.30	213,157,094.59
Management expenses	271,376,559.14	240,180,046.33
Research and development expenses	11,806,407.83	19,164,661.81
Finance costs	(80,670,587.12)	(109,342,377.48)
Including: Interest expenses	219,000,762.97	201,248,627.21
Interest income	301,076,798.81	312,077,228.08
Add: Other revenue	718,851.68	1,184,348.85
Gain from investment	1,129,607,431.27	241,665,184.80
Including: Gains from investment in associates and joint ventures	57,193,431.27	71,504,993.51
Gains from changes in fair values	–	(474,050.45)
Impairment losses of assets	(522,196.08)	(55,489.42)
Loss on credit impairment	(8,977,392.40)	(3,828,918.76)
Gains from disposal of assets	68,391.40	15,677.05
Operating profits	1,169,211,005.19	311,319,307.85
Add: Non-operating income	19,526.26	13,976.91
Less: Non-operating expenses	46,171.68	1,768,973.66
Total profits	1,169,184,359.77	309,564,311.10
Less: Income tax expenses	–	–
Net profits	1,169,184,359.77	309,564,311.10
Including: Net profits of the absorbed party before business combination under common control	–	–
Net profits attributable to the owners of the parent company	1,169,184,359.77	309,564,311.10
Other comprehensive income, net of tax	(140,067.90)	144,014.73
Total comprehensive income	1,169,044,291.87	309,708,325.83

**CHINA RESOURCES PHARMACEUTICAL COMMERCIAL GROUP
COMPANY LIMITED
STATEMENT OF CASH FLOWS
JANUARY TO JUNE 2026**

Unit: RMB

Item	January–June 2026	January–June 2025
I. Cash flows from operating activities:		
Cash received from the sales of goods and the rendering of services	9,052,309,457.22	9,085,340,088.63
Refund of taxes and levies	–	–
Cash received relating to other operating activities	18,891,990.25	20,366,799.09
Sub-total of cash inflows from operating activities	9,071,201,447.47	9,105,706,887.72
Cash paid for goods purchased and services received	8,523,328,323.91	8,720,953,740.49
Cash paid to and for employees	339,387,734.90	328,594,914.49
Payments of all types of taxes	93,056,706.64	92,329,580.88
Cash payments relating to other operating activities	159,121,007.78	156,798,983.97
Sub-total of cash outflows from operating activities	9,114,893,773.23	9,298,677,219.83
Net cash flow from operating activities	(43,692,325.76)	(192,970,332.11)
II. Cash Flow From Investing Activities:		
Cash received from investment recovery	4,508,404,230.82	9,781,911,020.00
Cash received from returns on investments	534,024,331.57	685,380,851.62
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	177,943.63	45,873.43
Net cash received from disposals of subsidiaries and other operating units	–	–
Cash received relating to other investing activities	–	–
Sub-total of cash inflows from investing activities	5,042,606,506.02	10,467,337,745.05
Cash paid to acquire fixed assets, intangible assets and other long-term assets	10,911,874.93	8,995,545.48
Cash paid for investments	5,055,100,000.00	12,937,465,566.62
Net cash paid for acquisition of subsidiaries and other operational units	–	–
Cash payments relating to other investing activities	–	–
Sub-total of cash outflows from investing activities	5,066,011,874.93	12,946,461,112.10
Net cash flow from investing activities	(23,405,368.91)	(2,479,123,367.05)

Item	January–June 2026	January–June 2025
III. Cash flow from financing activities:		
Cash received from capital contribution	–	–
Cash received from borrowings	3,200,000,000.00	2,495,000,000.00
Cash received from issuance of bonds	5,200,000,000.00	5,000,000,000.00
Cash payments relating to other financing activities	1,677,243,750.65	2,353,017,384.96
Sub-total of cash inflows from financing activities	10,077,243,750.65	9,848,017,384.96
Cash payments for debts settlement	4,584,597,256.52	573,536,463.57
Cash payments for distribution of dividends, profits, or interest expenses	1,400,299,858.16	1,266,572,348.10
Cash payments relating to other financing activities	3,901,879,229.20	5,231,622,025.19
Sub-total of cash outflows from financing activities	9,886,776,343.88	7,071,730,836.86
Net cash flow from financing activities	190,467,406.77	2,776,286,548.10
IV. Effect of foreign exchange rate changes on cash and cash equivalents	–	–
V. Net increase in cash and cash equivalents	123,369,712.10	104,192,848.94
Add: Opening balance of cash and cash equivalent	3,782,306,604.46	2,613,119,787.23
VI. Closing balance of cash and cash equivalents	3,905,676,316.56	2,717,312,636.17